CareDx, Inc. (NASDAQ:CDNA) Shares Sold by Rhumbline Advisers

Rhumbline Advisers cut its position in CareDx, Inc. (NASDAQ:CDNA) by 2.2% in the first quarter, Holdings Channel reports. The firm owned 79,384 shares of the company’s stock after selling 1,817 shares during the period. Rhumbline Advisers’ holdings in CareDx were worth $1,409,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Swiss National Bank boosted its position in shares of CareDx by 1.9% in the 4th quarter. Swiss National Bank now owns 98,600 shares of the company’s stock valued at $2,111,000 after purchasing an additional 1,800 shares during the period. Allspring Global Investments Holdings LLC increased its stake in CareDx by 59.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 327,343 shares of the company’s stock valued at $7,008,000 after purchasing an additional 122,356 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in CareDx in the 4th quarter valued at approximately $208,000. Nuveen Asset Management LLC increased its stake in CareDx by 15.5% in the 4th quarter. Nuveen Asset Management LLC now owns 448,113 shares of the company’s stock valued at $9,594,000 after purchasing an additional 60,050 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in CareDx by 6.5% in the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company’s stock valued at $406,000 after purchasing an additional 1,151 shares in the last quarter.

Analysts Set New Price Targets

CDNA has been the subject of several research analyst reports. Wall Street Zen downgraded CareDx from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. The Goldman Sachs Group dropped their price objective on CareDx from $34.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, April 17th. HC Wainwright reaffirmed a “neutral” rating and issued a $25.00 price objective on shares of CareDx in a research note on Monday, May 5th. Finally, Stephens reaffirmed an “overweight” rating and issued a $40.00 price objective on shares of CareDx in a research note on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CareDx has an average rating of “Moderate Buy” and an average target price of $30.33.

Insider Transactions at CareDx

In other CareDx news, Director William A. Hagstrom sold 30,000 shares of the business’s stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $17.45, for a total transaction of $523,500.00. Following the transaction, the director now owns 53,979 shares in the company, valued at $941,933.55. The trade was a 35.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christine Cournoyer sold 16,700 shares of the business’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total value of $235,971.00. Following the transaction, the director now owns 37,045 shares in the company, valued at approximately $523,445.85. This represents a 31.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 108,773 shares of company stock worth $1,843,890 over the last quarter. 4.40% of the stock is currently owned by insiders.

CareDx Stock Performance

CareDx stock opened at $19.03 on Thursday. The stock has a fifty day moving average of $17.55 and a two-hundred day moving average of $20.16. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of 16.55 and a beta of 2.18. CareDx, Inc. has a fifty-two week low of $13.48 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. The company had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a return on equity of 21.16% and a net margin of 19.79%. CareDx’s revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) earnings per share. On average, analysts forecast that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.